However, CTNNB1 expression was moderately correlated with B7-H3 (CD276), a new checkpoint target for cancer immunotherapy with an expression frequency of 91.8% in HCC (46), which suggested that CTNNB1-mutated HCC patients might escape immunotherapy through the non-classical immune checkpoint pathway, providing a novel direction for the treatment of CTNNB1-mutated HCC patients and precise decision-making for HCC management. This evidence concerns the gene CD276 and hepatocellular carcinoma.